NCT02649387 2026-02-10
MERIT
Mayo Clinic
Phase 2 Completed
Clinical Trials
56 trialsNCT03702725 2026-01-06
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Phase 1 Completed
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT02827617 2025-11-18
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Oncology Institute of Southern Switzerland
Completed
NCT02315768 2025-09-15
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
University of California, San Diego
Phase 1/2 Completed
NCT03207555 2025-09-02
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02558816 2025-07-24
OAsIs
Nantes University Hospital
Phase 1/2 Completed
NCT02956382 2025-07-18
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
Phase 1/2 Completed
NCT02303392 2025-06-10
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02899078 2025-05-18
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
University of California, Davis
Phase 1/2 Completed
NCT03295240 2025-05-13
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT03939182 2025-04-25
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02824029 2025-02-17
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02388048 2025-01-29
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT02643667 2025-01-08
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02207062 2025-01-07
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Completed
NCT02863718 2024-12-30
CLL12
German CLL Study Group
Phase 3 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT03129828 2024-12-13
ImbruVeRCHOP
Charite University, Berlin, Germany
Phase 1/2 Completed
NCT02268851 2024-11-15
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02927964 2024-10-16
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Stanford University
Phase 1/2 Completed
NCT02692248 2024-10-10
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT02532257 2024-09-24
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02420912 2024-03-20
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03525925 2024-03-18
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03323151 2024-01-18
PrE0404
PrECOG, LLC.
Phase 1/2 Completed
NCT03399513 2024-01-05
R-CHOEP-brut
University Hospital Muenster
Phase 2 Completed
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT04439006 2023-12-26
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02321540 2023-10-25
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02869633 2023-10-23
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT03267186 2023-08-01
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Stanford University
Phase 2 Completed
NCT03219047 2023-07-27
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT02309580 2023-05-09
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02758665 2023-01-17
CLL2-GiVe
University of Ulm
Phase 2 Completed
NCT03454165 2023-01-04
A Study of BNC105P Combined With Ibrutinib
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT03877055 2022-12-14
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02604511 2022-12-07
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02756247 2022-10-10
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02553941 2022-10-06
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
University of California, Davis
Phase 1 Completed
NCT03332498 2022-06-03
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02419560 2022-05-24
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
University of Virginia
Phase 1 Completed
NCT02542514 2022-04-14
iLOC
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02736617 2022-01-05
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT03045328 2021-09-29
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Stanford University
Phase 2 Completed
NCT02582320 2021-09-13
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
NCT02562898 2021-05-06
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT02626884 2021-04-08
IRENO
University of Cologne
Phase 2 Completed
NCT03755947 2021-02-02
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Phase 2 Completed
NCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed